|
•
|
(i) the borrowing of (i) $4,000 million under a new senior secured U.S. dollar denominated term loan facility (the ‘‘Term Loan Facility’’) and (ii) the entry into a new $300 million senior secured revolving credit
facility (the ‘‘New Revolving Credit Facility’’ and, together with the Term Loan Facility, the ‘‘New Senior Secured Credit Facilities’’);
|
|
•
|
the issuance of $500.0 million aggregate principal amount of 2026 Notes offered hereby; and
|
|
•
|
the issuance of $1,515.0 million aggregate principal amount of 2028 Notes offered hereby.
|
|
Sources of funds
|
Amount
|
Uses of funds
|
Amount
|
||||||
|
(dollars in millions)
|
(dollars in millions)
|
||||||||
|
Cash(a)
|
$
|
1,241.0
|
Equity Purchase Price
|
$
|
11,148.0
|
||||
|
Stock Consideration
|
5,773.0
|
||||||||
|
Cash Consideration
|
5,375.0
|
||||||||
|
Term Loan Facility(b)
|
4,000.0
|
Existing ICON Indebtedness and Existing PRA Indebtedness
|
1,631.0
|
||||||
|
ICON Equity(c)
|
5,773.0
|
Estimated fees and expenses related to the Transactions(d)
|
250.0
|
||||||
|
2026 Notes offered hereby
|
500.0
|
||||||||
|
2028 Notes offered hereby
|
1,515.0
|
||||||||
|
Total sources
|
$
|
13,029.0
|
Total uses
|
$
|
13,029.0
|
||||
|
(a)
|
Cash is derived from the actual combined cash and equivalents of ICON and PRA as of March 31, 2021. As of March 31, 2021, prior to giving effect to the Transactions, the combined company would have had cash and
cash equivalents of approximately $1,632.7 million and, after giving effect to the Transactions, would have had approximately $391.7 million of cash and cash equivalents. As of May 31, 2021, prior to giving effect to the Transactions, the
combined company would have had cash and cash equivalents of approximately $1,690.0 million. See ‘‘Summary—Summary PRA Historical Financial Data,’’ ‘‘Summary—Summary ICON Historical Financial Data,’’ ‘‘Use of Proceeds,’’ ‘‘Capitalization’’
and ICON’s Unaudited Pro Forma Condensed Combined Financial Statements (the ‘‘Pro Forma Financial Statements’’) incorporated by reference into this offering memorandum from ICON’s Current Report on Form 6-K filed by ICON on June 14, 2021
(the ‘‘Pro Forma 6-K’’) for additional information.
|
|
(b)
|
See ‘‘Summary—Financing Transactions’’ and ‘‘Description of Certain Other Indebtedness—New Senior Secured Credit Facilities.’’
|
|
(c)
|
Represents the stock portion of the consideration for the Merger of 0.4125 ordinary shares of ICON for each share of PRA based on a fixed exchange ratio, calculated using the ICON share price as of May 31, 2021.
See the Pro Forma 6-K for additional information, including for the number of PRA shares outstanding as of March 31, 2021.
|
|
(d)
|
Represents estimated fees and expenses associated with the Transactions, including financing fees, original issue discounts, legal, advisory and professional fees, and other transaction costs such as printing and
rating agency fees. To the extent any financing fees, original issue discounts and other fees and expenses exceed the estimated amounts, we expect to fund such amounts with cash of the combined company at the closing of the Transactions.
|
|
Year Ended December 31, 2020
|
Three Months Ended
March 31,
|
Twelve Months Ended
March 31,
2021
|
||||||||||||||
|
($ in thousands)
|
2020 |
2021 |
||||||||||||||
| Selected Pro Forma Statements of Operations Data: | ||||||||||||||||
|
Revenue
|
$
|
5,964,987
|
$
|
1,491,059
|
$
|
1,791,897
|
$
|
6,265,825
|
||||||||
|
Direct Costs
|
4,326,680
|
1,103,427
|
1,321,256
|
4,544,509
|
||||||||||||
|
Selling, general and administrative
|
1,036,446
|
384,683
|
221,626
|
873,389
|
||||||||||||
|
Depreciation and amortization
|
563,175
|
139,930
|
142,503
|
565,748
|
||||||||||||
|
Restructuring
|
18,089
|
—
|
—
|
18,089
|
||||||||||||
|
Total costs and expenses
|
$
|
5,944,390
|
$
|
1,628,040
|
$
|
1,685,385
|
$
|
6,001,735
|
||||||||
|
Income/(loss) from operations
|
$
|
20,597
|
$
|
(136,981
|
)
|
$
|
106,512
|
$
|
264,090
|
|||||||
|
Interest income
|
3,048
|
1,809
|
257
|
1,496
|
||||||||||||
|
Interest expense
|
(308,529
|
)
|
(83,729
|
)
|
(64,929
|
)
|
(289,729
|
)
|
||||||||
|
Income/(loss) before income taxes expense
|
$
|
(284,884
|
)
|
$
|
(218,901
|
)
|
$
|
41,840
|
$
|
(24,143
|
)
|
|||||
|
Income tax (expense)/credit
|
68,841
|
30,276
|
(1,090
|
)
|
37,475
|
|||||||||||
|
Income before share of earnings from equity method investments
|
$
|
(216,043
|
)
|
$
|
(188,625
|
)
|
$
|
40,750
|
$
|
13,332
|
||||||
| Share of equity method investments |
(366
|
)
|
—
|
(274
|
)
|
(640
|
)
|
|||||||||
| Net Income/(loss) |
$
|
(216,409
|
)
|
$
|
(188,625
|
)
|
$
|
40,476
|
$
|
12,692
|
||||||
| Net income attributable to noncontrolling interest |
(633
|
)
|
(633
|
)
|
—
|
— | ||||||||||
| Net Income/(loss) |
$
|
(217,042
|
)
|
$
|
(189,258
|
)
|
$
|
40,476
|
$
|
12,692
|
||||||
|
($ in thousands (except for
Pro Forma Cash Conversion and Ratios))
|
Twelve
Months Ended
March 31, 2021
|
|||
|
Other Financial Data:
|
||||
| Pro Forma EBITDA(1) | $ | 829,198 | ||
| Pro Forma Adjusted EBITDA(1) | $ | 1,005,735 | ||
| Pro Forma Further Adjusted EBITDA(1) |
$ | 1,155,735 | ||
| Pro Forma Adjusted Free Cash Flow(1)(8)(9) | $ | 1,043,214 | ||
| Pro Forma Cash Conversion(1)(8)(10) | 90 | % | ||
| Total Pro Forma Net Debt(2) | $ | 5,623,300 | ||
| Ratio of Total Pro Forma Net Debt to Pro Forma Further Adjusted EBITDA(2) | 4.90 to 1.00 | |||
|
(1)
|
Pro Forma EBITDA, Pro Forma Adjusted EBITDA, Pro Forma Further Adjusted EBITDA, Pro Forma Adjusted Free Cash Flow and Pro Forma Cash Conversion as presented in this offering memorandum are supplemental financial
measures that are not required by, or presented in accordance with, GAAP. We define (1) Pro Forma EBITDA as net income of the combined company before depreciation and amortization expense, interest
expense, net and provision for income taxes and net income attributable to noncontrolling interests; Pro Forma Adjusted EBITDA as Pro Forma EBITDA plus share of equity method investments,
stock-based compensation expense, certain transaction-related costs and restructuring charges; (3) Pro Forma Further Adjusted EBITDA as Pro Forma Adjusted EBITDA plus certain cost savings and
synergies expected to be realized as a result of the Merger; (4) Pro Forma Adjusted Free Cash Flow as Pro Forma Further Adjusted EBITDA minus capital expenditures; (5) Pro Forma Cash Conversion as
Adjusted Free Cash Flow divided by Pro Forma Further Adjusted EBITDA and (6) Total Pro Forma Net Debt as the principal amount (without adjustment for deferred financing costs or original issue
discount) of total debt of the combined company minus cash and cash equivalents of the combined company. Pro Forma EBITDA, Pro Forma Adjusted EBITDA, Pro Forma Further Adjusted EBITDA, Pro Forma Adjusted Free Cash Flow, Pro Forma Cash
Conversion and Total Pro Forma Net Debt are commonly used as measures of financial performance, and are used solely as performance measures. Pro Forma EBITDA, Pro Forma Adjusted EBITDA, Pro Forma Further Adjusted EBITDA, Pro Forma Adjusted
Free Cash Flow, Pro Forma Cash Conversion and Total Pro Forma Net Debt should not be considered measures of financial performance or liquidity under GAAP, and the items excluded from Pro Forma EBITDA, Pro Forma Adjusted EBITDA, Pro Forma
Further Adjusted EBITDA, Pro Forma Adjusted Free Cash Flow, Pro Forma Cash Conversion and Total Pro Forma Net Debt are significant components in understanding and assessing the combined company’s financial performance or liquidity. Pro
Forma EBITDA, Pro Forma Adjusted EBITDA, Pro Forma Further Adjusted EBITDA, Pro Forma Adjusted Free Cash Flow, Pro Forma Cash Conversion and Total Pro Forma Net Debt should not be considered in isolation or as alternatives to such GAAP
measures as net income, cash flows provided by or used in operating, investing or financing activities or other financial statement data presented in the financial statements of PRA and ICON or the pro forma financial statements of the
combined company as indicators of financial performance or liquidity. Since Pro Forma EBITDA, Pro Forma Adjusted EBITDA, Pro Forma Further Adjusted EBITDA, Pro Forma Adjusted Free Cash Flow, Pro Forma Cash Conversion and Total Pro Forma Net
Debt are not measures determined in accordance with GAAP and are susceptible to varying calculations, Pro Forma EBITDA, Pro Forma Adjusted EBITDA, Pro Forma Further Adjusted EBITDA, Pro Forma Adjusted Free Cash Flow, Pro Forma Cash
Conversion and Total Pro Forma Net Debt, as presented, may not be comparable to other similarly titled measures of other companies. Pro Forma EBITDA, Pro Forma Adjusted EBITDA, Pro Forma Further Adjusted EBITDA, Pro Forma Adjusted Free
Cash Flow, Pro Forma Cash Conversion and Total Pro Forma Net Debt have limitations as analytical tools, and should not be considered in isolation or as substitutes for analyzing our results as reported under GAAP.
|
|
($ in thousands (except for
Pro Forma Cash Conversion))
|
Twelve
Months Ended
March 31, 2021
|
|||
|
Net Income/(loss)
|
$
|
12,692
|
||
|
Depreciation and Amortization
|
$
|
565,748
|
||
|
Interest expense (net)
|
$
|
288,233
|
||
|
Provision for income taxes
|
$
|
(37,475
|
)
|
|
|
Pro Forma EBITDA
|
$
|
829,198
|
||
|
Share of equity method investments(3)
|
$
|
640
|
||
|
Stock based compensation expense(4)
|
$
|
164,262
|
||
|
Transaction related costs(5)
|
$
|
(6,454
|
)
|
|
|
Restructuring Charges(6)
|
$
|
18,089
|
||
|
Pro Forma Adjusted EBITDA
|
$
|
1,005,735
|
||
|
Cost savings and synergies(7)
|
$
|
150,000
|
||
|
Pro Forma Further Adjusted EBITDA
|
$
|
1,155,735
|
||
|
Capital expenditures(8)
|
$
|
112,521
|
||
|
Pro Forma Adjusted Free Cash Flow(8)(9)
|
$
|
1,043,214
|
||
|
Pro Forma Cash Conversion(8)(10)
|
90
|
%
|
||
|
(2)
|
Total Pro Forma Net Debt is equal to (x) the principal amount (without adjustment for deferred financing costs or original issue discount) of $6,015.0 million of total debt of the combined company minus (y) $391.7 million of cash and cash equivalents of the combined company, in each case, as of March 31, 2021 as reflected in the Pro Forma Adjusted column under ‘‘Capitalization’’ after giving
effect to the cash and cash equivalents used to consummate the Transactions.
|
|
(3)
|
Share of equity method investments include ICON’s share of gain/loss in respect of its 49% share in the voting interest of Oncacare, which was jointly established with a third party.
|
|
(4)
|
Stock based compensation expense reflects non-cash employee compensation expenses.
|
|
(5)
|
Transaction related charges include acquisition (including the Merger) related costs and changes to the fair value of acquisition consideration.
|
|
(6)
|
Restructuring charges include the cost of resource rationalizations following approval of restructuring plans adopted following a review of resource utilization
|
|
(7)
|
Represents an adjustment to reflect the anticipated annual ‘‘run rate’’ benefit from certain operational cost synergies expected to be fully realized by the end of the fourth fiscal year following the
consummation of the Transactions. These assumptions and estimates are inherently uncertain and subject to significant business, operational, economic and competitive uncertainties and contingencies. We cannot assure you that any or all of
these cost savings and cost synergies will be achieved in the anticipated amounts or within the anticipated timeframes or at all. See ‘‘Risk Factors—Risks Relating to the Merger and the Combined Company after Completion of the Merger—ICON
may be unable to realize anticipated cost and tax synergies and expects to incur substantial expenses related to the Merger.’’
|
|
(8)
|
Capital expenditures are defined as purchases of and additions to property, plant & equipment, net.
|
|
(9)
|
Pro Forma Adjusted Free Cash Flow is defined as Pro Forma Adjusted EBITDA minus capital expenditures.
|
|
(10)
|
Pro Forma Cash Conversion is defined as Pro Forma Adjusted Free Cash Flow divided by Pro Forma Adjusted EBITDA.
|